OmniAb, Inc. (NASDAQ:OABIW – Get Free Report) saw a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 18,488 shares, an increase of 98.0% from the July 30th total of 9,338 shares. Based on an average daily trading volume, of 6,868 shares, the days-to-cover ratio is presently 2.7 days.
OmniAb Stock Down 16.7%
Shares of OABIW opened at $0.25 on Friday. The firm’s fifty day simple moving average is $0.11 and its two-hundred day simple moving average is $0.10. OmniAb has a 12 month low of $0.04 and a 12 month high of $0.40.
About OmniAb
OmniAb, Inc is a clinical‐stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high‐throughput screening and bioinformatics, OmniAb aims to streamline the development of next‐generation biologics across a range of disease areas.
At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single‐cell screening capabilities.
See Also
- Five stocks we like better than OmniAb
- OneMain’s Yield Comes With a Catch
- 3 AI Infrastructure Stocks to Watch Beyond NVIDIA
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
